191 related articles for article (PubMed ID: 35604210)
1. Determining Susceptibility in
Sobel JD; Akins R
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0236621. PubMed ID: 35604210
[TBL] [Abstract][Full Text] [Related]
2. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.
Danby CS; Boikov D; Rautemaa-Richardson R; Sobel JD
Antimicrob Agents Chemother; 2012 Mar; 56(3):1403-6. PubMed ID: 22232293
[TBL] [Abstract][Full Text] [Related]
3. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Shahid Z; Sobel JD
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):354-6. PubMed ID: 19501794
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates.
Sobel JD; Sebastian S; Boikov DA
Mycoses; 2023 Jul; 66(7):563-565. PubMed ID: 36866967
[TBL] [Abstract][Full Text] [Related]
5. Anidulafungin treatment for fluconazole-resistant
Akdağ D; Pullukçu H; Yamazhan T; Metin DY; Sipahi OR; Ener B; Işıkgöz Taşbakan M
J Obstet Gynaecol; 2021 May; 41(4):665-666. PubMed ID: 32312119
[No Abstract] [Full Text] [Related]
6. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Adjapong G; Hale M; Garrill A
Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
[TBL] [Abstract][Full Text] [Related]
7. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Sobel JD; Sobel R
Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786
[TBL] [Abstract][Full Text] [Related]
8. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
Bitew A; Abebaw Y
BMC Womens Health; 2018 Jun; 18(1):94. PubMed ID: 29902998
[TBL] [Abstract][Full Text] [Related]
9. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
10. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.
Cross EW; Park S; Perlin DS
Microb Drug Resist; 2000; 6(2):155-61. PubMed ID: 10990271
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species.
Mondello F; De Bernardis F; Girolamo A; Cassone A; Salvatore G
BMC Infect Dis; 2006 Nov; 6():158. PubMed ID: 17083732
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
[TBL] [Abstract][Full Text] [Related]
14. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.
Gomaa SE; Abbas HA; Mohamed FA; Ali MAM; Ibrahim TM; Abdel Halim AS; Alghamdi MA; Mansour B; Chaudhary AA; Elkelish A; Boufahja F; Hegazy WAH; Yehia FAA
BMC Microbiol; 2024 Feb; 24(1):54. PubMed ID: 38341568
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of resistance and sensitivity of 1 200 strains of vulvovaginal candidiasis in China to five common antifungal drugs].
Fan LY; Liu ZH; Bai XN; Zong X
Zhonghua Fu Chan Ke Za Zhi; 2022 Aug; 57(8):601-607. PubMed ID: 36008287
[No Abstract] [Full Text] [Related]
16. Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
Ge SH; Wan Z; Li J; Xu J; Li RY; Bai FY
Antimicrob Agents Chemother; 2010 Aug; 54(8):3126-31. PubMed ID: 20516286
[TBL] [Abstract][Full Text] [Related]
17. First detection of mutated ERG11 gene in vulvovaginal Candida albicans isolates at Ouagadougou/Burkina Faso.
Dovo EE; Zohoncon TM; Tovo SF; Soubeiga ST; Kiendrebeogo IT; Yonli AT; Ouedraogo RA; Dabire AM; Djigma FW; Nadembega CW; Belemgnegre M; Ouedraogo P; Obiri-Yeboah D; Simpore J
BMC Infect Dis; 2022 Aug; 22(1):678. PubMed ID: 35941587
[TBL] [Abstract][Full Text] [Related]
18. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
Lynch ME; Sobel JD; Fidel PL
J Med Vet Mycol; 1996; 34(5):337-9. PubMed ID: 8912167
[TBL] [Abstract][Full Text] [Related]
19. Small molecules restore azole activity against drug-tolerant and drug-resistant
Alabi PE; Gautier C; Murphy TP; Gu X; Lepas M; Aimanianda V; Sello JK; Ene IV
mBio; 2023 Aug; 14(4):e0047923. PubMed ID: 37326546
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis.
Nagashima M; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 Feb; 22(2):124-6. PubMed ID: 26627336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
